The addition of MET to the RAPA‐treatment does not interfere with the inhibitory effect on Gpam expression, but it does prevent the consequent promotion of hypertriglyceridemia, potentially through its restoration of hepatic Ldlr expression (see “Steatosis and hyperlipidemia” below). Here, LDLR is linked to hypertriglyceridemia.